Advertisement
Advertisement
September 17, 2024
Boston Scientific Closes Acquisition of Silk Road Medical
September 17, 2024—Boston Scientific Corporation announced the close of its acquisition of Silk Road Medical, Inc. the developer of transcarotid artery revascularization (TCAR) for the treatment of carotid artery disease.
According to Boston Scientific, the acquisition includes a purchase price of $27.50 per share, reflecting an enterprise value of approximately $1.18 billion.
On June 18, 2024, Boston Scientific announced it had entered into a definitive agreement to acquire Silk Road.
“Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their patients through our significant commercial reach,” commented Cat Jennings of President, Vascular, Peripheral Interventions at Boston Scientific, in the press release. “The integration of the TCAR platform into our portfolio means we can offer a treatment option for patients suffering from carotid artery disease that can reduce the risk of stroke and lead to improved patient outcomes.”
Advertisement
Advertisement
